CEL-SCI Corporation (NYSE American: CVM) announced that a manuscript based on data from its Phase 3 IT-MATTERS clinical trial evaluating ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE